An observational study in Frailty, Sarcopenia and Selenium, sponsored by Ankara City Hospital Bilkent. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Ankara City Hospital Bilkent · Observational
Chronic kidney disease (CKD) is a significant public health issue with an increasing prevalence worldwide. In patients undergoing hemodialysis (HD) in particular, various factors-such as chronic inflammation, oxidative stress, nutritional disorders, and micronutrient deficiencies-can negatively affect muscle health and physical function. Selenium, an essential trace element with potent antioxidant properties, has been shown to be present at low levels in these patients and may be associated with muscle strength. Sarcopenia and frailty are critical clinical conditions in HD patients that diminish quality of life and increase the risk of hospitalization and mortality. This study aims to evaluate the relationship between serum selenium levels, sarcopenia, and frailty in patients undergoing chronic hemodialysis, and to investigate whether selenium levels might serve as a potential biomarker for these clinical conditions.
Sarcopenia is a significant muscular disorder characterized by a decline in muscle strength and muscle mass, which can lead to a loss of physical performance. Frailty, on the other hand, is a clinical condition arising from a reduction in physiological reserves, rendering an individual more vulnerable to stressors; it is associated with an increased risk of falls, functional dependence, hospitalization, and mortality. In patients undergoing chronic hemodialysis, common mechanisms-such as inflammation, oxidative stress, metabolic disturbances, malnutrition, and reduced physical activity-contribute to the development of both conditions. While previous studies have suggested that low selenium levels may be linked to a decline in muscle strength and mass, research simultaneously examining serum selenium levels in relation to both sarcopenia and frailty among chronic hemodialysis patients remains limited. This study aims to investigate the relationship between serum selenium levels and the presence of sarcopenia and frailty in patients receiving chronic hemodialysis, as well as to compare the clinical, laboratory, and physical performance characteristics of patients with and without selenium deficiency. It is anticipated that the findings will contribute to a better understanding of the factors associated with sarcopenia and frailty in this patient population and help evaluate the potential of serum selenium levels to serve as a biomarker.
1,233 studies on the registry are indexed under Frailty; 435 are open to participants now.
This study's enrollment of 78 is below the median of 211 across 503 observational studies indexed under Frailty.
Browse Frailty studies →Ankara City Hospital Bilkent is the lead sponsor of 439 studies on the registry; 110 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients over 18 years of age receiving hemodialysis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
hemodialysis patients
Other: FRAIL scale · Other: sarc-f · Other: time up go test · Other: hand grip strength
frailty
sarkopenia
functional performance
hand grip strength using hand dynamometer
frailty
FRAIL scale: The FRAIL scale consists of 5 items, each scored on a scale of 0-1. The total score ranges from 0 to 5. Based on the total score, 0 is classified as robust/non-frail, 1-2 as prefrail, and 3 as frail.
Time frame: 20 weeks
sarcopenia sarc-f
This is a questionnaire used for sarcopenia screening, which has been validated and tested for reliability in Turkish. Its components are defined as follows: Strength (S), Assistance with walking (A), Rising from a chair (R), Climbing stairs (C), and Falls (F). The questionnaire consists of 5 questions, each scored on a scale of 0-2 points. The recommended cut-off value for this scale is ≥4 points. A score of 4 or higher indicates a risk for sarcopenia.
Time frame: 20 weeks
time up go test
Physical Performance: The "Timed Up and Go" (TUG) test was administered to assess the functional performance of the participants. The TUG test is a practical and rapidly applied assessment that measures walking speed, functional mobility, and dynamic balance. For the test, individuals were asked to sit on an armless chair with their feet touching the floor; upon the command "go," they were instructed to stand up, walk along a marked 3-meter path, turn around, and return to sit back down in the chair. During this process, the time taken by each individual to complete the activity was recorded.
Time frame: 20 weeks
hand grip strength
Handgrip strength (HGS) was measured using a hydraulic hand dynamometer (Baseline). Measurements were performed three times on the hand without a fistula, and the highest value was recorded.
Time frame: 20 weeks
selenium
Serum selenium concentrations were measured using inductively coupled plasma-mass spectrometry (ICP-MS) with an Agilent 7500 ICP-MS instrument (Agilent Technologies, USA), in accordance with the laboratory's analytical procedure (code: TIP-TÇT-52). Results were recorded in micrograms per liter (µg/L). Based on a previous study, a serum selenium level of \<70 µg/L was defined as selenium deficiency in our study.
Time frame: 20 weeks
Plan to share: Undecided
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ankara City Hospital Bilkent →